Beta-interferon clinical trials using MRI in patients with multiple sclerosis.

被引：0
|
作者：
Lebrun, C [1 ]
机构：
[1] Hop Louis Pasteur, Neurol Serv, F-06002 Nice, France
来源：
REVUE NEUROLOGIQUE | 2001年 / 157卷 / 8-9期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Magnetic resonance imaging has revolutionized management of patients with multiple sclerosis. This tool provides information on a dynamic process never visualized before, optimizing diagnostic capacities and formalizing the course of the lesion load. Follow-in clinical assessment and performance testing, MRI constitutes a second line tool for following the course of patients with multiple sclerosis in phase II and III trials. We reviewed the correlations between the radiological and clinical findings and the methodology of published trials on beta interferons in remitting, secondarily progressive and early onset multiple sclerosis.
引用
收藏
页码：761 / 767
页数：7
相关论文
共 50 条
  • [41] THROMBOTIC MICROANGIOPATHY WITH SEVERE RENAL FAILURE SECONDARY TO BETA-INTERFERON TREATMENT FOR MULTIPLE SCLEROSIS
    Orvain, C.
    Augusto, J. F.
    Marc, G.
    Subra, J. F.
    Sayegh, J.
    [J]. HAEMATOLOGICA, 2012, 97 : 733 - 733
  • [42] EFFECTS OF BETA-INTERFERON TREATMENT ON VIRAL-INFECTIONS AND RELAPSES OF MULTIPLE-SCLEROSIS
    PANITCH, HS
    KATZ, E
    JOHNSON, KP
    [J]. NEUROLOGY, 1994, 44 (04) : A358 - A358
  • [43] Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
    Rudge, P
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (02) : 123 - 125
  • [44] Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
    K. O'Rourke
    C. Walsh
    M. Hutchinson
    [J]. Journal of Neurology, 2007, 254 : 1547 - 1554
  • [45] MRI as an outcome in multiple sclerosis clinical trials
    Daumer, M.
    Neuhaus, A.
    Morrissey, S.
    Hintzen, R.
    Ebers, G. C.
    [J]. NEUROLOGY, 2009, 72 (08) : 705 - 711
  • [46] Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
    O'Rourke, Killian
    Walsh, Cathal
    Hutchinson, Michael
    [J]. JOURNAL OF NEUROLOGY, 2007, 254 (11) : 1547 - 1554
  • [47] The ABN relapse based multiple sclerosis beta-interferon stopping criterion is not clinically useful
    O'Rourke, K
    Hutchinson, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (01): : 140 - 140
  • [48] Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis
    A. Parry
    R. Corkill
    A. M. Blamire
    J. Palace
    S. Narayanan
    D. Arnold
    P. Styles
    P. M. Matthews
    [J]. Journal of Neurology, 2003, 250 : 171 - 178
  • [49] Clinical significance of neutralizing antibodies to interferon beta in patients with Multiple Sclerosis
    Zarkesh-Esfahani, Sayyed Hamid
    Zare, Nasrin
    Gharagozloo, Marjan
    Shaygannejad, Vahid
    [J]. JOURNAL OF IMMUNOLOGY, 2016, 196
  • [50] Contribution of clinical and MRI to evaluation of NEDA (No Evidence of Disease Activity) from the pivotal trial of interferon beta-1b in multiple sclerosis.
    Goodin, D. S.
    Reder, A. T.
    Koelbach, R.
    Pohl, C.
    Wicklein, E. -M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 837 - 837
12345